HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Overview of attention for article published in Frontiers in Pharmacology, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 9,152 followers.

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib #lymphoma #lymsm https://t.co/hhJ3zKWUki

21 Jun 2022

Reply Repost Favourite

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib https://t.co/V9Ory3xEUl

20 Jun 2022

Reply Repost Favourite

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib #lymphoma #lymsm https://t.co/Q8udy2oUlj

20 Jun 2022

Reply Repost Favourite

New article: HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib https://t.co/ZPOvFHSUW6 #MCL #lymsm #hematology https://t.co/ywgcVPKCCI

20 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.